What is Tenofovir?
Tenofovir is a potent antiviral medication belonging to the class of drugs known as nucleotide reverse transcriptase inhibitors (NRTIs). It plays a critical role in the management of chronic infections caused by the Human Immunodeficiency Virus (HIV) and the Hepatitis B Virus (HBV). By inhibiting viral replication, Tenofovir helps to control these infections, improve patient outcomes, and reduce the risk of transmission. It is available in several formulations, often in combination with other antiretroviral agents, and also as a prodrug form that enhances its oral bioavailability and cellular uptake. Common brand names associated with Tenofovir include Viread (tenofovir disoproxil fumarate) and Vemlidy (tenofovir alafenamide). Understanding its mechanism, uses, and potential side effects is crucial for healthcare providers and patients alike.
Mechanism of Action
Tenofovir functions by mimicking a natural building block of viral DNA, specifically adenosine. As a nucleotide analog, it enters viral cells and undergoes intracellular phosphorylation to its active diphosphate form. This active metabolite, tenofovir diphosphate, competes with the natural substrate, deoxyadenosine triphosphate, for incorporation into the growing viral DNA chain by the viral reverse transcriptase enzyme (in HIV) or DNA polymerase (in HBV).
Once incorporated into the viral DNA strand, tenofovir acts as a chain terminator. Because it lacks the necessary 3'-hydroxyl group required for the addition of subsequent nucleotides, the elongation of the viral DNA chain is halted. This inhibition of reverse transcriptase or DNA polymerase effectively prevents the virus from replicating its genetic material and producing new infectious virions. This disruption of the viral life cycle is the cornerstone of Tenofovir's antiviral efficacy.
Receptor Interactions:
Tenofovir's primary interaction is with the viral enzymes reverse transcriptase (for HIV) and DNA polymerase (for HBV). It is phosphorylated intracellularly by host cell kinases to its active diphosphate form. This active metabolite then competes with endogenous deoxynucleotide triphosphates for binding to the enzyme's active site. Upon incorporation into the nascent viral DNA strand, it causes premature chain termination due to the absence of a 3'-hydroxyl group necessary for phosphodiester bond formation.
Clinical Uses & Indications
Tenofovir is a cornerstone in the treatment of several significant viral infections. Its efficacy and safety profile have established it as a key component in combination antiretroviral therapy (cART) for HIV infection and in the management of chronic Hepatitis B.
HIV Infection:
Tenofovir, particularly in its prodrug forms (tenofovir disoproxil fumarate - TDF, and tenofovir alafenamide - TAF), is widely used for the treatment of HIV-1 infection in adults and pediatric patients. It is typically part of a combination regimen with other antiretroviral drugs, such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or integrase strand transfer inhibitors (INSTIs). The goal of treatment is to achieve and maintain viral suppression (undetectable viral load), restore immune function (increase CD4+ T-cell counts), and reduce the risk of HIV-related morbidity and mortality.
Hepatitis B Virus (HBV) Infection:
Tenofovir, primarily TDF and TAF, is also FDA-approved for the treatment of chronic Hepatitis B virus infection in adults and pediatric patients. In HBV infection, Tenofovir acts as a potent inhibitor of the HBV DNA polymerase, effectively suppressing viral replication. Treatment aims to reduce viral load, normalize liver enzymes (ALT), improve liver histology, and decrease the risk of complications such as cirrhosis and hepatocellular carcinoma. It is often considered a first-line therapy for chronic HBV due to its high efficacy and generally favorable safety profile.
Pre-exposure Prophylaxis (PrEP):
A combination product containing tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is approved and widely used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection in adults and adolescents at high risk. This strategy is a vital public health tool in HIV prevention efforts.
Dosage & Administration
The dosage and administration of Tenofovir depend on the specific formulation (TDF or TAF), the indication (HIV or HBV), the patient's age, weight, and renal function. It is crucial to follow the prescribing physician's instructions precisely.
Common Dosage Forms:
- Tablets: Tenofovir is most commonly administered orally in the form of tablets.
- Combination Tablets: It is frequently available in fixed-dose combination tablets with other antiretroviral agents (e.g., emtricitabine, elvitegravir, cobicistat).
Typical Dosing Regimens:
- Tenofovir Disoproxil Fumarate (TDF): For HIV treatment, chronic HBV treatment, and PrEP, the typical oral dose is 300 mg once daily.
- Tenofovir Alafenamide (TAF): For HIV treatment, the typical oral dose is 25 mg once daily. For chronic HBV treatment, the typical oral dose is 25 mg once daily. TAF generally requires a lower dose compared to TDF due to its more efficient delivery to target cells and lower plasma concentrations.
Administration Instructions:
- Tenofovir tablets can be taken with or without food.
- It is important to take the medication at the same time each day to maintain consistent drug levels in the body.
- For patients with impaired renal function, dose adjustments may be necessary based on creatinine clearance. Regular monitoring of kidney function is recommended.
Side Effects & Safety
While Tenofovir is generally well-tolerated, like all medications, it can cause side effects. The specific side effects and their frequency can vary between the two prodrugs, TDF and TAF, with TAF generally associated with fewer renal and bone adverse events compared to TDF.
Common Side Effects:
- Diarrhea
- Nausea
- Vomiting
- Headache
- Dizziness
- Abdominal pain
- Fatigue
- Rash
Serious Side Effects:
- Lactic Acidosis: A rare but serious metabolic complication characterized by the buildup of lactic acid in the blood. Symptoms include rapid breathing, fatigue, muscle pain, and abdominal discomfort.
- Hepatotoxicity: Exacerbation of hepatitis B infection upon discontinuation of the drug, severe liver damage, or liver failure.
- Renal Impairment: Including acute kidney injury and Fanconi syndrome (a disorder of kidney tubule function). Symptoms may include increased thirst and urination, muscle weakness, and bone pain. TDF has been more strongly associated with renal issues than TAF.
- Bone Mineral Density Reduction: Decreased bone mineral density leading to fractures, particularly with long-term TDF use. TAF has shown a better safety profile regarding bone density.
- Immune Reconstitution Inflammatory Syndrome (IRIS): Occurs in patients with advanced HIV infection who start cART, leading to an exaggerated inflammatory response to opportunistic infections.
Contraindications:
- Hypersensitivity to Tenofovir or any component of the formulation.
- Severe renal impairment (dosage adjustments or discontinuation may be necessary).
Note: Patients should be advised to report any new or worsening symptoms to their healthcare provider immediately. Regular monitoring of kidney function, liver function, and bone density may be required during treatment.
Drug Interactions
Tenofovir can interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. It is essential for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking.
Notable Drug Interactions:
- Nephrotoxic Agents: Concomitant use with other drugs that can harm the kidneys (e.g., certain antibiotics like aminoglycosides, nonsteroidal anti-inflammatory drugs (NSAIDs), diuretics like furosemide, and other antiretrovirals like cidofovir) can increase the risk of renal toxicity. Dose adjustments or avoidance may be necessary.
- Didanosine: Coadministration of TDF with didanosine can increase didanosine plasma concentrations, potentially leading to pancreatitis, peripheral neuropathy, and lactic acidosis. This combination is generally not recommended.
- Lopinavir/Ritonavir: While TDF can be used with lopinavir/ritonavir, it may increase the risk of renal adverse events. TAF has a different interaction profile and is often preferred in regimens containing ritonavir-boosted protease inhibitors.
- Anticonvulsants: Certain anticonvulsants, such as carbamazepine and phenytoin, can decrease plasma concentrations of Tenofovir, potentially reducing its efficacy.
- Herbal Products: St. John's Wort may decrease plasma concentrations of some antiretrovirals, though its specific interaction with Tenofovir is less well-defined, caution is advised.
The interaction profile can differ slightly between TDF and TAF, with TAF generally having fewer interactions related to renal transport proteins (like P-gp and BCRP) compared to TDF.
Molecular Properties
Tenofovir is a fascinating molecule with specific chemical and physical properties that dictate its biological activity and pharmacokinetic behavior.
Chemical Structure and Formula:
Tenofovir is an acyclic nucleoside phosphonate analog of adenosine monophosphate. Its chemical structure is characterized by an adenine base linked to a phosphonomethoxypropyl side chain.
- Molecular Formula: C9H14N5O4P (for the base molecule, Tenofovir)
- Molecular Weight: Approximately 287.21 g/mol (for the base molecule, Tenofovir)
SMILES Notation:
The Simplified Molecular Input Line Entry System (SMILES) provides a linear representation of the molecule's structure. For Tenofovir, the SMILES notation is:
Nc1ncnc2c1ncn2[C@@H](CO)OCP(=O)(O)O
This notation encodes the connectivity and stereochemistry of the molecule, detailing the arrangement of atoms and bonds, including the chiral center indicated by [C@@H].
Structure Description:
The molecule consists of an adenine base (a purine derivative) attached via a glycosidic-like bond to a 2-(phosphonomethoxy)propyl group. Unlike natural nucleosides, Tenofovir is a phosphonate, meaning the phosphate group is directly attached to a carbon atom via a P-C bond, rather than a P-O-C linkage. This phosphonate structure contributes to its stability against enzymatic hydrolysis and its ability to be phosphorylated intracellularly. The stereochemistry at the carbon atom bearing the hydroxyl group ([C@@H] in SMILES) is important for its biological activity.
Physical Properties:
Tenofovir itself is a white to off-white crystalline powder. Its prodrug forms, Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF), are designed to improve oral absorption and bioavailability. TDF is a fumarate salt, while TAF is a more stable prodrug with improved cellular uptake and lower systemic exposure, leading to a better safety profile concerning renal and bone toxicity.
Frequently Asked Questions
What is Tenofovir used for?
Tenofovir is primarily used to treat infections caused by the Human Immunodeficiency Virus (HIV) and the Hepatitis B Virus (HBV). It is also used for pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk individuals.
What are the side effects of Tenofovir?
Common side effects include diarrhea, nausea, headache, and fatigue. More serious potential side effects, particularly associated with the TDF formulation, include kidney problems (renal impairment, Fanconi syndrome), bone density loss, and lactic acidosis. Tenofovir alafenamide (TAF) generally has a better safety profile regarding kidney and bone health.
How does Tenofovir work?
Tenofovir is a nucleotide reverse transcriptase inhibitor. It works by mimicking a natural building block of viral DNA. Once activated inside the cell, it gets incorporated into the growing viral DNA chain, acting as a chain terminator and preventing the virus (HIV or HBV) from replicating.
Is Tenofovir safe during pregnancy?
The use of Tenofovir during pregnancy should be discussed with a healthcare provider. While studies have not shown a clear increase in birth defects, potential risks and benefits must be carefully weighed. Tenofovir is often considered a preferred agent for HIV treatment in pregnant individuals due to its safety profile compared to some older drugs.
Can I take Tenofovir with other medications?
Tenofovir can interact with various medications, especially those that can affect kidney function or are processed by similar cellular pathways. It is crucial to inform your doctor about all medications you are taking to avoid potentially harmful interactions. Some combinations, like Tenofovir with certain antibiotics or diuretics, may require dose adjustments or avoidance.
Analyze Tenofovir with MolForge
Understanding the intricate molecular properties and potential interactions of drugs like Tenofovir is fundamental to advancing pharmaceutical research and development. MolForge leverages cutting-edge AI to provide deep insights into molecular behavior, predict drug efficacy, and identify novel therapeutic opportunities. Explore the detailed chemical structure, physicochemical properties, and potential applications of Tenofovir and countless other molecules. Discover the power of AI in accelerating your drug discovery journey by visiting our platform at MolForge Dashboard.